Merck Restructures Human Health Division for Enhanced Portfolio Execution

23 February 2026

Key highlights

Merck creates Oncology and Specialty, Pharma & Infectious Diseases units.
Jannie Oosthuizen and Brian Foard appointed as unit leaders.
Merck is conducting around 80 Phase 3 studies.
Over 20 new growth drivers expected in the coming years.

Restructuring for Enhanced Execution

Merck is reorganizing its Human Health division to improve commercial execution across its diverse therapeutic areas. The new structure includes two main units: Oncology and Specialty, Pharma & Infectious Diseases.

Leadership Appointments

Jannie Oosthuizen has been appointed as executive vice president and president of the Oncology unit. Brian Foard will lead the Specialty, Pharma & Infectious Diseases unit, joining Merck from Sanofi.

Stay informed with chemXplore Weekly →

Pipeline and Growth

Merck is currently conducting approximately 80 Phase 3 studies and anticipates more than 20 new growth drivers in the coming years, many with blockbuster potential.

Strategic Focus

The restructuring aims to sustain Merck's leadership in oncology while supporting a growing number of product launches across its expanding portfolio.